122,602 Shares in Obalon Therapeutics Inc (OBLN) Obtained by William Blair Investment Management LLC

122,602 Shares in Obalon Therapeutics Inc (OBLN) Obtained by William Blair Investment Management LLC

William Blair Investment Management LLC bought a new stake in Obalon Therapeutics Inc (NASDAQ:OBLN) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 122,602 shares of the company’s stock, valued at approximately $1,311,000.

Several other hedge funds have also made changes to their positions in OBLN. Interwest Venture Management Co. acquired a new stake in shares of Obalon Therapeutics during the fourth quarter valued at approximately $21,712,000. Kornitzer Capital Management Inc. KS boosted its stake in shares of Obalon Therapeutics by 0.7% in the first quarter. Kornitzer Capital Management Inc. KS now owns 420,335 shares of the company’s stock valued at $4,493,000 after buying an additional 3,105 shares during the last quarter. C WorldWide Group Holding A S boosted its stake in shares of Obalon Therapeutics by 97.8% in the first quarter. C WorldWide Group Holding A S now owns 197,805 shares of the company’s stock valued at $2,115,000 after buying an additional 97,805 shares during the last quarter. Meadow Creek Investment Management LLC acquired a new stake in shares of Obalon Therapeutics during the first quarter valued at approximately $659,000. Finally, Handelsbanken Fonder AB boosted its stake in shares of Obalon Therapeutics by 200.0% in the first quarter. Handelsbanken Fonder AB now owns 60,000 shares of the company’s stock valued at $641,000 after buying an additional 40,000 shares during the last quarter. Institutional investors own 3.74% of the company’s stock.

Shares of Obalon Therapeutics Inc (NASDAQ:OBLN) traded up 2.82% during mid-day trading on Friday, hitting $10.22. The stock had a trading volume of 24,256 shares. The stock has a 50 day moving average price of $10.49 and a 200 day moving average price of $10.17. Obalon Therapeutics Inc has a 52 week low of $8.27 and a 52 week high of $15.88. The firm’s market cap is $171.61 million.

Obalon Therapeutics (NASDAQ:OBLN) last posted its quarterly earnings results on Wednesday, May 10th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.14. The firm had revenue of $1.47 million during the quarter, compared to the consensus estimate of $1.60 million. Equities research analysts expect that Obalon Therapeutics Inc will post ($1.75) EPS for the current fiscal year.

OBLN has been the topic of several research analyst reports. Zacks Investment Research cut Obalon Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, April 26th. ValuEngine upgraded Obalon Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday. Canaccord Genuity restated a “buy” rating on shares of Obalon Therapeutics in a report on Monday, April 17th. Finally, BTIG Research restated a “buy” rating and set a $20.00 target price on shares of Obalon Therapeutics in a report on Sunday, March 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $16.25.

About Obalon Therapeutics

Obalon Therapeutics, Inc is a United States-based commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company’s product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:OBLN”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding OBLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Obalon Therapeutics Inc (NASDAQ:OBLN).

Related posts

Leave a Comment